


GW/TMH:gte 02/17/05
PATENT
Attorney Reference Number 6395-64908-01



EXPRESS MAIL LABEL NO. EV514608418US
DATE OF DEPOSIT: February 17, 2005
Application Number 09/826,115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/826,115

Filed: April 4, 2001

Confirmation No. 4134

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1648

Attorney Reference No. 6395-64908-01

MAIL STOP RCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(4)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Also listed and enclosed is a copy of International PCT Publication No. WO 92/02548, published in French. An English abstract for this publication is provided. Applicants respectfully request that all the documents listed on the accompanying form PTO-1449 be listed as references cited on the issued patent.

Applicants are filing this Information Disclosure Statement ("IDS") along with a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, Deposit Account No. 02-4550 Authority is provided on the accompanying transmittal letter.


GW/TMH:gte 02/17/05
PATENT
Attorney Reference Number 6395-64908-01

EXPRESS MAIL LABEL NO. EV514608418US
DATE OF DEPOSIT: February 17, 2005
Application Number 09/826,115


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Gwynedd Warren, Ph.D.
Registration No. 45,200

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6395-64908-01
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	WO 92/02548 (French w/English translation)	20 Feb. 1992	Institut Pasteur
		WIPO/PCT	WO 02/072036	29 Sept. 2002	Yale University & L2 Diagnostics, LLC
		WIPO/PCT	WO 02/083903	24 Oct 2002	Brown University Research Foundation
		Japan	JP 89025725 (English Abstract only)	May 1989	ZH Biseibutsu Kagaku Ken
		Japan	JP 53133627 (English Abstract only)	Nov 1978	Nippon Seibutsu KK
		Japan	JP 63004895 (English Abstract only)	1963	Saikin Seizai Yoka
		Japan	JP 63105682 (English Abstract only)	23 Oct 1986	Mitsubishi Kasei Corp
		Japan	JP 65000611 (English Abstract only)	1965	Nippon Seibutsu KK
		Japan	JP 67025408 (English Abstract only)	1967	Okuj
		Japan	JP 7265093 (English Abstract only)	Oct 1995	Tokyo To Shinkei Kagaku Sogo Kenkyusho


OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		ABERLE <i>et al.</i> , "A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms," <i>J. Immunol.</i> 163:6756-6761, 1999
		FONSECA <i>et al.</i> , "Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice," <i>Vaccine</i> 12:279-285, 1994

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6395-64908-01
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

	JACOBS <i>et al.</i> , "High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model," <i>J. Virol.</i> 66:2086-2095, 1992
	JACOBS, "A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge," <i>Clinical Science</i> 85:117-122, 1993
	MASON <i>et al.</i> , "Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1," <i>Virology</i> 161:262-267, 1987
	MONATH, "Flaviviruses," <i>Virology</i> (R.N. Fields, ed.) 763-814, 1990
	PINCUS <i>et al.</i> , "Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis," <i>Virology</i> 187:290-297, 1992
	RAMELOW <i>et al.</i> , "Detection of tick-borne encephalitis virus RNA in ticks (<i>Ixodes ricinus</i>) by the polymerase chain reaction," <i>J. Virological Methods</i> 45:115-119, 1993
	SCHALICH <i>et al.</i> , "Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions," <i>J. Virol.</i> 70(7):4549-4557, 1996
	SMITHBURN <i>et al.</i> , "A neurotropic virus isolated from the blood of a native of uganda," <i>Am. J. Trop. Med.</i> 20: 471-492, 1940

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	